A Clinical Trial of TQB3909 Tablets in Combination With Azacitidine for the Treatment of Myeloid Malignancies

Inclusion Criteria: * Voluntary and signed informed consent, good compliance * Age: ≥18 years old (at the time of signing the informed consent); expected survival time greater than 3 months. * Diagnosis of one of the following diseases: 1. Acute Myeloid Leukemia (AML): 2. Myelodysplastic Syndromes (MDS) 3. Major organ functions are normal. 4. Fertile male and female subjects agree to use contraception during the study and for 6 months after the study ends. Exclusion Criteria: * Comorbidities and Medical History: 1. Diagnosis of or current concomitant malignancy within 3 years prior to the first dose; 2. Presence of multiple factors affecting oral drug intake and/or absorption; 3. Major surgical procedures or significant traumatic injuries within 28 days prior to the first dose; 4. History of arterial/venous thrombotic events within 6 months prior to the first dose; 5. History of psychiatric drug abuse that cannot be discontinued, or psychiatric disorders; 6. Presence of any severe and/or uncontrolled disease in the subject. * Tumor-related Symptoms and Treatment: 1. Diagnosis of Acute Promyelocytic Leukemia (APL), Myelodysplastic Syndromes/Myeloproliferative Neoplasms (MDS/MPN); 2. Presence of leukemia central nervous system (CNS) involvement or high suspicion of CNS involvement but unable to confirm; 3. Subjects with extramedullary disease only in AML; 4. Presence of life-threatening severe leukemia-related complications; * Study Treatment-related: 1. Received live vaccines within 4 weeks prior to the first dose, or planned to receive live vaccines during the study period; 2. Participated in other clinical trials involving anti-tumor drugs within 4 weeks prior to the first dose.

Reproduced word-for-word from the public registry record — the study team can answer questions about it.